NIRvana Sciences Awarded $3 Million Phase IIb SBIR Grant from NIH

NIRvana Sciences, Inc., the leading developer of synthetic bacteriochlorins and chlorins, today announced that it has been awarded a $3 Million Phase IIb SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). This multi-year Phase IIb grant, “New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cytometry,” will be used to accelerate development and commercialization of a new class of fluorescent dyes emitting between 700nm-1000nm that will increase the performance capabilities of flow cytometers. Flow cytometry is a heavily used instrumentation platform for understanding our body’s immune system. With many new NIRvana dyes, researchers and clinicians will be able to run more complex experiments enabling them to develop a better understanding of how our immune system fights infectious diseases and cancers leading to the faster development of new, more effective vaccines and drugs.